tl;dr
Billionaire Stanley Druckenmiller's Duquesne Family Office has invested over $1 billion in three lesser-known stocks in the tech and healthcare sectors as of Q1 2025. The largest holdings are Natera Inc. ($521.48 million), Teva Pharmaceutical Industries ($252.955 million), and Coupang Inc. ($252.659...
Billionaire Stanley Druckenmiller’s Duquesne Family Office has invested over $1 billion in under-the-radar tech and healthcare stocks, with major positions in Natera Inc., Teva Pharmaceutical, and Coupang Inc., which together comprise 33% of its $3.06 billion portfolio.
As of Q1 2025, the firm's largest holding is in Natera Inc. (NTRA), a tech company specializing in genetic testing for early detection of hereditary conditions, including cancer. Duquesne owns approximately 3.402 million NTRA shares valued at $521.48 million.
The firm also holds 14.879 million shares of Teva Pharmaceutical Industries (TEVA), an Israel-based generic medicines manufacturer, worth about $252.955 million. Additionally, Duquesne has invested heavily in Coupang Inc. (CPNG), a South Korean e-commerce giant, with over 9.3 million shares valued at roughly $252.659 million.
Together, these three investments total more than $1.02 billion, representing a significant 33% of the portfolio. Other notable holdings include Woodward Inc. (WWD) at $226.13 million, Philip Morris International (PM) at $193.67 million, and Coherent (COHR) at $175.27 million.
During the same period, the firm reduced its stakes in Seagate Technology (STX), Skechers USA (SKX), United Airlines (UAL), and SLM Corp (SLM), signaling a strategic shift in allocations within its diversified portfolio.